Clarithromycin in treatment of early Lyme disease: a pilot study

Antimicrob Agents Chemother. 1996 Feb;40(2):468-9. doi: 10.1128/AAC.40.2.468.

Abstract

Forty-one patients with erythema migrans were enrolled in an open-labelled pilot study of oral clarithromycin, 500 mg twice daily for 21 days, for the treatment of early Lyme disease. Immediately posttherapy, pretreatment signs and symptoms resolved among 91% of the 33 evaluable patients. At 6 months, all 28 of the evaluable patients were well. Clarithromycin shows promise as an effective agent for the treatment of early Lyme disease and warrants further study.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Aged, 80 and over
  • Anti-Bacterial Agents / therapeutic use*
  • Clarithromycin / therapeutic use*
  • Female
  • Humans
  • Lyme Disease / drug therapy*
  • Male
  • Middle Aged

Substances

  • Anti-Bacterial Agents
  • Clarithromycin